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Concomitant thyroid disease is not unusual among patients with primary hyperparathyroidism. However, the simultaneous
occurrence of parathyroid and thyroid carcinoma is extremely rare. We report a 38-year-old man with primary
hyperparathyroidism who presented with osteitis fibrosa cystica complicated with pathologic femoral neck fracture.
Preoperative investigation for exclusion of multiple endocrine neoplasia did not find evidence of medullary thyroid
carcinoma or pheochromocytoma, but imaging studies revealed the presence of nodules in the right lobe and a parathyroid
lesion over the left inferior pole of the thyroid gland. Total thyroidectomy, left parathyroidectomy, and bipolar
hemiarthroplasty of the left hip were then performed simultaneously. The resected specimens were pathologically
identified as papillary thyroid carcinoma and parathyroid carcinoma, respectively. After the operation, 131I ablation therapy
was administered at a dose of 120 mCi. Additional doses of 30 mCi were given yearly as serum thyroglobulin level
became elevated. Serum calcium level remained normal during yearly follow-up. Although parathyroid carcinoma is
an uncommon cause of parathyroid hormone-dependent hypercalcemia, it should nonetheless be given due consideration
because its surgical approach differs from that of parathyroid adenoma. As the coexistence of parathyroid and non-
medullary thyroid carcinoma has previously been reported, the possibility of both malignancies must also be considered
in the setting of primary hyperparathyroidism with thyroid nodules. If confirmed with preoperative parathyroid scintigraphic
and other laboratory studies, an optimal outcome may be achieved with complete resection of both tumors at the
time of initial operation, followed by adjunctive therapy. [J Chin Med Assoc 2005;68(2):87–91]
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Introduction
Since the introduction of routine serum calcium mea-
surement in the 1970s, primary hyperparathyroid-
ism has become one of the most commonly diag-
nosed endocrine diseases worldwide.1 Concomitant
thyroid disease is not unusual among patients with
primary hyperparathyroidism.2 From published studies,
the coexistence of non-medullary thyroid cancer is
found in 2.4–3.7% of patients operated on for primary
hyperparathyroidism.3 This high incidence of thyroid
cancer, which is greater than that in the general pop-
ulation (< 0.01%), signifies the need for heightened
clinical vigilance. Conversely, parathyroid carcinoma
is rare and accounts for less than 1% of patients with
primary hyperparathyroidism.4 PubMed and
MEDLINE searches yielded only 3 previous reports of
synchronous parathyroid and non-medullary thyroid
carcinoma.5–7 This report is the first in the Chinese
medical literature of a case of hyperfunctioning para-
thyroid carcinoma and concomitant papillary thyroid
carcinoma.
Case Report
A 38-year-old man with a history of renal stones
requiring lithotripsy 6 years previously was referred to
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our orthopedic clinic because of limping and weakness
in both hips. Multiple bone lesions were identified on
radiographic studies and bone scan. Biopsy of the
pubic bone was pathologically consistent with osteitis
fibrosa cystica. Serum biochemistry was significant for
hypercalcemia (4.05 mmol/L; normal range, 2.2–
2.6 mmol/L). The level of intact parathyroid hormone
(PTH) was elevated (107 pmol/L; normal range, 1.8–
7.3 pmol/L), whereas the level of thyroid-stimulating
hormone was within normal limits (2 mIU/L).
Ultrasound demonstrated 2 enlarged parathyroid
glands adjoining the right thyroid lobe, and a 4 = 3 =
3 cm mass over the left lower thyroid pole. Fine-needle
aspiration cytology of this mass revealed marked nu-
clear pleomorphism with prominent nucleoli, sug-
gesting carcinoma of the parathyroid gland.
A few days later, the patient was admitted to
hospital for left femoral neck fracture after falling off
a motorcycle. Preoperative screening for evidence of
multiple endocrine neoplasia (MEN) showed normal
serum levels of calcitonin and carcinoembryonic
antigen, and urinary catecholamine concentrations
were all within the reference range (Table 1). 201Tl–
99mTc subtraction scintigraphy disclosed a hot spot
over the inferior-lateral aspect of the left thyroid
gland, and some residual 201Tl activity over the superior-
medial aspect of the right thyroid gland and superior-
lateral aspect of the left thyroid gland. In addition,
there was a cold area over the superior pole of the right
thyroid gland in the 99m Tc scan when compared with
the 201Tl scan (Figure 1). Computerized tomography
(CT) scan of the neck confirmed the presence of a left
parathyroid lesion, but also incidentally revealed a
calcified lesion in the right thyroid lobe (Figure 2).
During the operation, because the concurrence of
both papillary thyroid and parathyroid carcinoma was
confirmed by frozen section, it was decided that the
Table 1. Laboratory data for the patient
Serum or urinary level Normal reference range
Serum parameters
   Calcitonin, pmol/L 2.2 11< 2.9
   CEA, +g/L 0.6 < 10.
   Fasting glucose, mmol/L 4.3 3.9–6.1
   Fasting insulin, pmol/L 12,683.8 B 1 894.9–6,212.8
Urinary parameters
   Dopamine, nmol/d 177.8 1 327–2,943
   Epinephrine, nmol/d 43 < 122.3
   Norepinephrine, nmol/d 86.4  65.6–505.3
   VMA, nmol/d 185.8 B  5.9–64.9
CEA = carcinoembryonic antigen; VMA = vanillylmandelic acid; B = elevated.
Figure 1. (A) 201Tl, (B) 99mTc, and (C) subtraction scans
demonstrating intense uptake in the left lower thyroid pole. Two
areas (the left and right upper thyroid gland) had residual thallium
activity after subtraction.
Figure 2. A large mass was identified in the left lower thyroid pole
on computerized tomography scan of the neck. A calcified lesion
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surgical approach should comprise total thyroidectomy
and left parathyroidectomy. Bipolar arthroplasty was
also conducted for the left femoral neck fracture.
Histologic examination of the resected specimens
subsequently confirmed the presence of both para-
thyroid carcinoma (Figure 3) and papillary thyroid
carcinoma (Figure 4), with metastasis demonstrated
in 1 lymph node. The postoperative course was un-
eventful, except for transient hypocalcemia. Three
weeks later, the patient received 131I therapy at an
ablative dose of 120 mCi. Thereafter, he was maintained
on thyroid hormone replacement therapy and calcium
supplementation. Subsequent 131I therapy at 30 mCi
was administered yearly, as the serum thyroglobulin
level became elevated after thyroxine withdrawal. Serum
levels of calcium and PTH remained normal during
yearly follow-up for more than 6 years.
Discussion
Although parathyroid carcinoma is an uncommon
cause of primary hyperparathyroidism, its incidence
may increase in line with an increased incidence of
primary hyperparathyroidism.2 Importantly, parathy-
roid carcinoma should be considered in the differen-
tial diagnosis of PTH-dependent hypercalcemia, as
morbidity and mortality associated with this diagnosis
are substantial, and optimal outcomes are associated
with complete tumor resection (i.e. en bloc removal
of the lesion together with the ipsilateral thyroid lobe
and isthmus, and removal of any contiguous tissues
to which the tumor adheres) at the time of initial
operation.4 All too often, the diagnosis is made retro-
spectively when hypercalcemia recurs because of
local tumor spread or distant metastases. The average
time between surgery and first recurrence is approxi-
mately 3 years. Once the tumor has recurred, complete
cure is unlikely.4
Figure 3. The parathyroid tissue showed haphazard sheets or
trabeculae of tumor cells with fragmented thick fibrous septa and
frank invasive features (hematoxylin & eosin stain, = 100).
Figure 4. The thyroid tissue revealed irregular papillary fronds
infiltrating the desmoplastic stroma (hematoxylin & eosin stain,
= 200).
There are several presenting features of primary
hyperparathyroidism that should suggest a malignant
rather than benign course. A summary of features that
might lead one to suspect parathyroid carcinoma is
shown in Table 2.4 The presence of some of these
features in our patient, in particular the excessively
Table 2. Features suggesting parathyroid carcinoma in primary hyperparathyroidism
• Hypercalcemia: serum calcium > 3.5 mmol/L
• Associated with other signs and symptoms of hypercalcemia
• High serum PTH level: > 3–10 times above the upper limit of normal
• High serum alkaline phosphatase level: above the upper limit of normal
• Elevated levels of _- and `-subunits of hCG
• Palpable neck mass
• Recurrent laryngeal nerve palsy in patients without previous neck surgery
• Simultaneous renal and overt skeletal involvement
• Coexisting with recurrent severe pancreatitis, peptic ulcer disease, and anemia
hCG = human chorionic gonadotropin; PTH = parathyroid hormone. Adapted from reference 4.
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high serum calcium and PTH levels, should alert one
to the possibility of parathyroid carcinoma. Benign
primary hyperparathyroidism usually presents with
low serum levels of PTH and calcium, but it should
be noted that the distinction between benign and
malignant disease may be difficult on clinical grounds
in some patients with benign primary hyperpara-
thyroidism who present with high serum levels of PTH
and calcium. It is preferable to have a high index of
suspicion for parathyroid carcinoma when the above
features are present, rather than to miss the opportunity
for surgical cure by failing to consider such carcinoma
in the differential diagnosis.
In more than 80% of cases, primary hyperpara-
thyroidism is attributable to a solitary parathyroid
adenoma.8 However, up to 10% of cases may result
from a hereditary disorder, such as MEN type 1 and
type 2A.8 MEN1 (typically with pituitary, parathyroid
and pancreatic tumors) represents 2–4% of all cases of
primary hyperparathyroidism,9 and patients tend to
present at a younger age with more severe hypercal-
cemia than those with sporadic disease,8 which typical-
ly manifests at about 55 years of age.4 Although our
patient was relatively young and had severe hyper-
calcemia, he has had no evidence of MEN1. His sella
turcica appeared of normal size radiographically.
Abdominal CT images revealed neither pancreatic nor
adrenal tumors. His elevated serum fasting insulin
level (12,684 pmol/L) might reflect underlying insu-
lin resistance as he was overweight (body mass index =
25.6 kg/m2).
Primary hyperparathyroidism occurs less common-
ly in patients with MEN2A (typically with medullary
thyroid carcinoma, pheochromocytoma and hyper-
parathyroidism). However, pheochromocytoma occurs
in 50% of these patients,8 which exposes them to
the risk of intraoperative hypertensive crisis if alpha-
adrenergic blockade is not achieved preoperatively. As
for medullary thyroid carcinoma, its exclusion was
warranted in this patient because of the thyroid nodule
identified via neck CT scan. The possibility of MEN2A
was low because of the normal serum calcitonin level,
lack of family history, and normal urinary catecholamine
concentrations, except for a high urinary level of
vanillylmandelic acid (VMA). Although the specificity
of urinary VMA is high for the diagnosis of pheo-
chromocytoma (95%),10 ingestion of certain foods
within 72 hours before testing (e.g. coffee, tea,
chocolate, vanilla, and some fruits and vegetables,
especially bananas), and ingestion of some drugs such
as tricyclic antidepressants, and diuretics in doses
sufficient to produce sodium depletion, may account
for false-positive results.10,11 This patient was treated
with large doses of furosemide (40 mg/day) during
urinary sample collection. As he had no hypertension
and no identifiable adrenal tumor on CT images, the
possibility of pheochromocytoma and, therefore, of
MEN type 2A was unlikely.
There are false-positive and false-negative results of
201Tl and 99mTc subtraction imaging.12 False-negative
results are attributed to the small size of many lesions,
abnormal 99mTc uptake by the thyroid gland, attenua-
tion of counts from ectopic glands located deep in the
neck or mediastinum, technical factors such as patient
movement, and abnormal 99mTc uptake by a parathyroid
adenoma. Various lesions may accumulate 201Tl but
not 99mTc, resulting in a false-positive subtraction scan.
These lesions include the following: papillary, follicu-
lar, and anaplastic carcinomas of the thyroid; chronic
lymphocytic thyroiditis; benign adenoma and nodules
of the thyroid; sarcoid lymph node; Hodgkin’s lym-
phoma; and metastatic lymph nodes. The subtraction
image of this patient, besides the prominent left para-
thyroid lesion, also showed 2 areas of residual 201Tl
activity. The cold area in the 99mTc scan compared with
the 201Tl scan might account for the right residual
activity in the subtraction scan. It might represent
uptake by the papillary thyroid carcinoma. The left
area of residual 201Tl activity might have resulted from
patient movement during the procedure, since the
subtraction image showed asymmetry of the salivary
glands.
There have been only 3 previous case reports of
synchronous parathyroid carcinoma and non-medullary
thyroid carcinoma. In 1979, a Japanese article described
a patient with hyperfunctioning parathyroid carcinoma
combined with papillary thyroid carcinoma.5 In another
case, occult parathyroid carcinoma was discovered
incidentally after a patient had undergone thyroidec-
tomy for papillary thyroid carcinoma and Hashimoto’s
thyroiditis.6 The third case of hyperfunctioning
parathyroid carcinoma and concomitant thyroid
carcinoma, without a previous history of neck irradia-
tion, was reported in the English literature.2 The
present case, then, would be the fourth. These cases
illustrate the fact that concomitant hyperfunctioning
parathyroid carcinoma and non-medullary thyroid
carcinoma should not be overlooked, despite the rarity
of such occurrence.
In the diagnosis of primary hyperparathyroidism,
the association between malignant thyroid disease
(medullary or non-medullary thyroid cancer) and neo-
plastic parathyroid tissue must be given due consid-
eration. Besides the investigations of MEN, an
integrated approach using a combination of parathyroid
scan, neck ultrasound, and other imaging modalities,
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may be required. As prognosis depends largely on
successful resection of all malignant tumors at the time
of initial operation, any thyroid or parathyroid lesion
observed via any imaging study must be taken serious-
ly, even if different imaging studies show discrepant
results, as in our case. Failing to consider the malignant
potential of all lesions may lead to inadequate surgical
resection and, therefore, to a suboptimal outcome.
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